Advanced Triple Negative Breast Cancer
Conditions
Keywords
Chemoimmunotherapy, Stage IV TNBC, Sacituzumab, N-803, PD-L1 t-haNK, Cyclophosphamide
Brief summary
This is a phase 1b/2 open-label study to evaluate the safety and efficacy of sacituzumab govitecan-hziy in combination with chemoimmunotherapy (cyclophosphamide, N-803, and PD-L1 t-haNK) in subjects with Triple Negative Breast Cancer (TNBC) after at least 2 prior treatments for metastatic disease.
Detailed description
In part 1 of phase 1b, 3 to 6 subjects will be sequentially enrolled starting at dose level 1 and will be assessed for dose limiting toxicities (DLTs). Dose level cohorts for sacituzumab govitecan-hziy are as follows: * Dose level 1: Sacituzumab govitecan-hziy (7.5 mg/kg IV) * Dose level 2: Sacituzumab govitecan-hziy (10 mg/kg IV) * Dose level 1 (if needed): Sacituzumab govitecan-hziy (5.0 mg/kg IV) In part 2 of phase 1b, dose expansion will occur when the RP2D has been determined. An additional 4 subjects may be enrolled, for a total of up to 10 subjects at the RP2D. Following part 2 of the phase 1b portion of the study, the Safety Review Committee (SRC) will meet to determine if enrollment into phase 2 should proceed. In the phase 2 portion of the study, 22 subjects will be enrolled at the RP2D in the first stage of Simon's two stage optimal design. If ≥ 9 of 22 subjects exhibit a confirmed response, the study will proceed to the second stage. If the study proceeds to the second stage, an additional 41 subjects will be enrolled for a total of 63 subjects in the phase 2. If ≥ 27 of the 63 subjects exhibit a confirmed response, the combination therapy will be considered for further development. All subjects may receive up to 17 cycles (ie, 51 weeks) of treatment administered in 3-week cycles.
Interventions
BIOLOGICALN-803
Dose: 15 μg/kg subcutaneously (SC) Frequency: administered on Day 8 of each cycle (every 3 weeks)
BIOLOGICALPD-L1 t-haNK
Dose: \ 2 × 10\^9 cells intravenously (IV) Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)
DRUGSacituzumab Govitecan-Hziy
Phase 1b: Dose level 1: Sacituzumab govitecan-hziy (7.5 mg/kg IV) Dose level 2: Sacituzumab govitecan-hziy (10 mg/kg IV) Dose level -1 (if needed): Sacituzumab govitecan-hziy (5.0 mg/kg IV) Phase 2: Dose based on Phase 1b Recommended Phase 2 Dose (IV) Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)
DRUGCyclophosphamide
Dose: 25 mg capsules taken twice per day by mouth (PO) Frequency: to be taken Days 1-15 and 15-19 of each cycle (every 3 weeks)
Sponsors
ImmunityBio, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years. 2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or Independent Ethics Committee (IEC) guidelines. 3. Histologically confirmed stage IV TNBC. Subjects must have had at least 2 prior treatments for TNBC. TNBC is defined as breast cancer that lacks estrogen receptor (ER) and progesterone receptor (PgR) expression (both ≤ 1% of tumor cell nuclei), and human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification (IHC 0 or 1+, or IHC 2+ and fluorescence in situ hybridization \[FISH\]-), according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline criteria, as evaluated by local institutions. 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2. 5. Have at least 1 measurable lesion of ≥ 1.0 cm and/or non-measurable disease evaluable in accordance with RECIST V1.1. 6. Ability to attend required study visits and return for adequate follow-up, as required by this protocol. 7. Agreement to practice effective contraception for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception while on study and for at least 5 months after the last dose of study treatment. Non-sterile male subjects must agree to use a condom while on study and for up to 5 months after the last dose of study treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs), oral contraceptives, and abstinence.
Exclusion criteria
1. Have previously received or are currently receiving treatment with sacituzumab govitecan-hziy. 2. Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment-related complications. 3. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma). 4. History of organ transplant requiring immunosuppression. 5. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis). 6. Inadequate organ function, evidenced by the following laboratory results: 1. Absolute neutrophil count (ANC) \< 1500 cells/mm3. 2. Platelet count \< 75,000 cells/mm3. 3. Hemoglobin \< 9 g/dL. 4. Total bilirubin greater than the upper limit of normal (ULN; unless the subject has documented Gilbert's syndrome). 5. Aspartate aminotransferase (AST \[SGOT\]) or alanine aminotransferase (ALT \[SGPT\]) \> 2.5 × ULN (\> 5 × ULN in subjects with liver metastases). 6. Alkaline phosphatase (ALP) levels \> 2.5 × ULN (\> 5 × ULN in subjects with liver metastases, or \>10 × ULN in subjects with bone metastases). 7. Serum creatinine \> 2.0 mg/dL or 177 μmol/L. 7. Uncontrolled hypertension (systolic \> 160 mm Hg and/or diastolic \> 110 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication. 8. Current chronic daily treatment (continuous for \> 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed. 9. Known hypersensitivity to any component of the study medication(s). 10. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications. 11. Known uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1) gene polymorphism resulting in reduced function. 12. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol. 13. Concurrent participation in any interventional clinical trial. 14. Pregnant and nursing women. A negative serum pregnancy test during screening and a negative pregnancy test within 72 hours prior to the first dose must be documented before study drug is administered to a female subject of child-bearing potential.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events | 30 days after last dose, up to 65 weeks and 5 days |
Countries
United States
Participant flow
Pre-assignment details
Only the Phase 1b portion of the study enrolled participants. The study was terminated early, so no participants were enrolled on the Phase 2 portion of the study.
Participants by arm
| Arm | Count |
|---|---|
| Sacituzumab Govitecan-hziy 7.5 mg/kg IV for All Subjects Sacituzumab plus chemoimmunotherapy (cyclophosphamide, N-803, and PD-L1 t-haNK) Sacituzumab govitecan-hziy 7.5 mg/kg IV for all subjects N-803: Dose: 15 μg/kg subcutaneously (SC)
Frequency: administered on Day 8 of each cycle (every 3 weeks)
PD-L1 t-haNK: Dose: \
2 × 10\^9 cells intravenously (IV)
Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks) | 3 |
| Total | 3 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Progressive Disease | 2 |
Baseline characteristics
| Characteristic | Sacituzumab Govitecan-hziy 7.5 mg/kg IV for All Subjects |
|---|---|
| Age, Continuous | 50.7 years STANDARD_DEVIATION 15.95 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Histologically confirmed stage IV TNBC. Subjects must have had at least 2 prior treatments for TNBC | 3 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 1 Participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 1 / 3 |
| other Total, other adverse events | 3 / 3 |
| serious Total, serious adverse events | 3 / 3 |
Outcome results
Primary
Number of Participants With Treatment Emergent Adverse Events
Time frame: 30 days after last dose, up to 65 weeks and 5 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| All Subjects | Number of Participants With Treatment Emergent Adverse Events | 3 Participants |